The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Janet S. Staats
No Relationships to Disclose
 
Cliburn Chan
No Relationships to Disclose
 
Michael Roger Harrison
Consulting or Advisory Role - Bayer; Exelixis; Genentech; Sanofi
Speakers' Bureau - Genentech
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Genentech; Medivation/Astellas; Pfizer
 
Peter H. O'Donnell
Stock and Other Ownership Interests - Allergan
Honoraria - Algeta ASA; American Medical Forum; Astellas Pharma; AstraZeneca; Genentech/Roche; Harrison Consulting Group; Inovio Pharmaceuticals; Janssen Biotech; Kantar Health; Merck; Novartis; Parexel; Quintiles; Seagen; Xcenda
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Named as co-inventor on a pending patent for a genomic prescribing system for medication prescribing.
Expert Testimony - TERA; Triage Cancer
Travel, Accommodations, Expenses - Merck
Other Relationship - Advance Medical
 
Kristen A Batich
Patents, Royalties, Other Intellectual Property - Patent US20160271240A1
 
Tianling Chen
Employment - Acerta Pharma
Stock and Other Ownership Interests - AstraZeneca; Merck
 
Cecile Krejsa
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma; AstraZeneca; Seagen
 
Raquel Izumi
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
Consulting or Advisory Role - Trigemina
Patents, Royalties, Other Intellectual Property - Patents pending for Acerta Pharma
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Kent J. Weinhold
Consulting or Advisory Role - Merck